PortalPublikationenUpfront stem cell transplantation for newly diagnosed multip...

Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT

Standard

Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. / Gagelmann, Nico; Eikema, Diderik-Jan; de Wreede, Liesbeth C; Rambaldi, Alessandro; Iacobelli, Simona; Koster, Linda; Caillot, Denis; Blaise, Didier; Remémyi, Péter; Bulabois, Claude-Eric; Passweg, Jakob; Leleu, Xavier; Zver, Samo; Kobbe, Guido; Ljungman, Per; Chevallier, Patrice; Ringhoffer, Mark; Martin, Murray; Salmenniemi, Urpu; Poiré, Xavier; Lenhoff, Stig; Pioltelli, Pietro; Mordini, Nicola; Delforge, Michel; Garderet, Laurent; Schönland, Stefan; Yakoub-Agha, Ibrahim; Kröger, Nicolaus.

in: BONE MARROW TRANSPL, Jahrgang 56, Nr. 1, 01.2021, S. 210-217.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gagelmann, N, Eikema, D-J, de Wreede, LC, Rambaldi, A, Iacobelli, S, Koster, L, Caillot, D, Blaise, D, Remémyi, P, Bulabois, C-E, Passweg, J, Leleu, X, Zver, S, Kobbe, G, Ljungman, P, Chevallier, P, Ringhoffer, M, Martin, M, Salmenniemi, U, Poiré, X, Lenhoff, S, Pioltelli, P, Mordini, N, Delforge, M, Garderet, L, Schönland, S, Yakoub-Agha, I & Kröger, N 2021, 'Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT', BONE MARROW TRANSPL, Jg. 56, Nr. 1, S. 210-217. https://doi.org/10.1038/s41409-020-01007-w

APA

Gagelmann, N., Eikema, D-J., de Wreede, L. C., Rambaldi, A., Iacobelli, S., Koster, L., Caillot, D., Blaise, D., Remémyi, P., Bulabois, C-E., Passweg, J., Leleu, X., Zver, S., Kobbe, G., Ljungman, P., Chevallier, P., Ringhoffer, M., Martin, M., Salmenniemi, U., ... Kröger, N. (2021). Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. BONE MARROW TRANSPL, 56(1), 210-217. https://doi.org/10.1038/s41409-020-01007-w

Vancouver

Gagelmann N, Eikema D-J, de Wreede LC, Rambaldi A, Iacobelli S, Koster L et al. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. BONE MARROW TRANSPL. 2021 Jan;56(1):210-217. https://doi.org/10.1038/s41409-020-01007-w

Bibtex

@article{d11ca7f9faec40fea97f0f9164aa3e34,
title = "Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT",
abstract = "We analyzed newly diagnosed multiple myeloma patients with del(17p) and/or t(4;14) undergoing either upfront single autologous (auto), tandem autologous (auto-auto) or tandem autologous/reduced-intensity allogeneic (auto-allo) stem cell transplantation. 623 patients underwent either auto (n = 446), auto-auto (n = 105), or auto-allo (n = 72) between 2000 and 2015. 46% of patients had t(4;14), 45% had del(17p) while 9% were reported having both abnormalities. Five-year overall survival (OS) was 51% (95% confidence interval [CI], 45-58%) for single auto, 60% (95% CI, 49-72%) for auto-auto, and 67% (95% CI, 53-80%) for auto-allo (p = 0.187). Five-year progression-free survival (PFS) was 17% (95% CI, 12-22%), 33% (95% CI, 22-43%), and 34% (95% CI, 21-38%; p = 0.048). Five-year relapse rate was 82, 63, and 56%, while non-relapse mortality was 1, 4, and 10%. In multivariable analysis, in t(4;14) with single auto as reference, auto-auto (hazard ratio [HR], 0.44; p = 0.007) and auto-allo (HR, 0.45; p = 0.018) were associated with better PFS. In terms of t(4;14) and OS, auto-auto appeared to improve outcome compared with single auto (HR, 0.49; p = 0.096). In del(17p), outcome in PFS was similar between single auto and auto-auto, while auto-allo appeared to improve PFS (HR, 0.65; p = 0.097). No significant difference in OS was identified between the groups in patients with del(17p).",
author = "Nico Gagelmann and Diderik-Jan Eikema and {de Wreede}, {Liesbeth C} and Alessandro Rambaldi and Simona Iacobelli and Linda Koster and Denis Caillot and Didier Blaise and P{\'e}ter Rem{\'e}myi and Claude-Eric Bulabois and Jakob Passweg and Xavier Leleu and Samo Zver and Guido Kobbe and Per Ljungman and Patrice Chevallier and Mark Ringhoffer and Murray Martin and Urpu Salmenniemi and Xavier Poir{\'e} and Stig Lenhoff and Pietro Pioltelli and Nicola Mordini and Michel Delforge and Laurent Garderet and Stefan Sch{\"o}nland and Ibrahim Yakoub-Agha and Nicolaus Kr{\"o}ger",
year = "2021",
month = jan,
doi = "10.1038/s41409-020-01007-w",
language = "English",
volume = "56",
pages = "210--217",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT

AU - Gagelmann, Nico

AU - Eikema, Diderik-Jan

AU - de Wreede, Liesbeth C

AU - Rambaldi, Alessandro

AU - Iacobelli, Simona

AU - Koster, Linda

AU - Caillot, Denis

AU - Blaise, Didier

AU - Remémyi, Péter

AU - Bulabois, Claude-Eric

AU - Passweg, Jakob

AU - Leleu, Xavier

AU - Zver, Samo

AU - Kobbe, Guido

AU - Ljungman, Per

AU - Chevallier, Patrice

AU - Ringhoffer, Mark

AU - Martin, Murray

AU - Salmenniemi, Urpu

AU - Poiré, Xavier

AU - Lenhoff, Stig

AU - Pioltelli, Pietro

AU - Mordini, Nicola

AU - Delforge, Michel

AU - Garderet, Laurent

AU - Schönland, Stefan

AU - Yakoub-Agha, Ibrahim

AU - Kröger, Nicolaus

PY - 2021/1

Y1 - 2021/1

N2 - We analyzed newly diagnosed multiple myeloma patients with del(17p) and/or t(4;14) undergoing either upfront single autologous (auto), tandem autologous (auto-auto) or tandem autologous/reduced-intensity allogeneic (auto-allo) stem cell transplantation. 623 patients underwent either auto (n = 446), auto-auto (n = 105), or auto-allo (n = 72) between 2000 and 2015. 46% of patients had t(4;14), 45% had del(17p) while 9% were reported having both abnormalities. Five-year overall survival (OS) was 51% (95% confidence interval [CI], 45-58%) for single auto, 60% (95% CI, 49-72%) for auto-auto, and 67% (95% CI, 53-80%) for auto-allo (p = 0.187). Five-year progression-free survival (PFS) was 17% (95% CI, 12-22%), 33% (95% CI, 22-43%), and 34% (95% CI, 21-38%; p = 0.048). Five-year relapse rate was 82, 63, and 56%, while non-relapse mortality was 1, 4, and 10%. In multivariable analysis, in t(4;14) with single auto as reference, auto-auto (hazard ratio [HR], 0.44; p = 0.007) and auto-allo (HR, 0.45; p = 0.018) were associated with better PFS. In terms of t(4;14) and OS, auto-auto appeared to improve outcome compared with single auto (HR, 0.49; p = 0.096). In del(17p), outcome in PFS was similar between single auto and auto-auto, while auto-allo appeared to improve PFS (HR, 0.65; p = 0.097). No significant difference in OS was identified between the groups in patients with del(17p).

AB - We analyzed newly diagnosed multiple myeloma patients with del(17p) and/or t(4;14) undergoing either upfront single autologous (auto), tandem autologous (auto-auto) or tandem autologous/reduced-intensity allogeneic (auto-allo) stem cell transplantation. 623 patients underwent either auto (n = 446), auto-auto (n = 105), or auto-allo (n = 72) between 2000 and 2015. 46% of patients had t(4;14), 45% had del(17p) while 9% were reported having both abnormalities. Five-year overall survival (OS) was 51% (95% confidence interval [CI], 45-58%) for single auto, 60% (95% CI, 49-72%) for auto-auto, and 67% (95% CI, 53-80%) for auto-allo (p = 0.187). Five-year progression-free survival (PFS) was 17% (95% CI, 12-22%), 33% (95% CI, 22-43%), and 34% (95% CI, 21-38%; p = 0.048). Five-year relapse rate was 82, 63, and 56%, while non-relapse mortality was 1, 4, and 10%. In multivariable analysis, in t(4;14) with single auto as reference, auto-auto (hazard ratio [HR], 0.44; p = 0.007) and auto-allo (HR, 0.45; p = 0.018) were associated with better PFS. In terms of t(4;14) and OS, auto-auto appeared to improve outcome compared with single auto (HR, 0.49; p = 0.096). In del(17p), outcome in PFS was similar between single auto and auto-auto, while auto-allo appeared to improve PFS (HR, 0.65; p = 0.097). No significant difference in OS was identified between the groups in patients with del(17p).

U2 - 10.1038/s41409-020-01007-w

DO - 10.1038/s41409-020-01007-w

M3 - SCORING: Journal article

C2 - 32710010

VL - 56

SP - 210

EP - 217

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 1

ER -